Supernus Pharmaceuticals Inc [SUPN] stock prices are up 1.74% to $49.22 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SUPN shares have gain 2.39% over the last week, with a monthly amount glided 11.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on October 09, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $65 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on July 30, 2025, and kept the price target unchanged to $42. On February 19, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $57 on January 06, 2025. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $36 on September 11, 2024.
The stock price of Supernus Pharmaceuticals Inc [SUPN] has been fluctuating between $29.16 and $51.78 over the past year. Currently, Wall Street analysts expect the stock to reach $64 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $49.22 at the most recent close of the market. An investor can expect a potential return of 30.03% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
The Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 665.12M for trailing twelve months, representing a drop of -1.71%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Supernus Pharmaceuticals Inc [NASDAQ:SUPN]’s Current Ratio is 2.58. Also, the Quick Ratio is 2.43, while the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 4.15, the price to book ratio is 2.60 and price to earnings (TTM) ratio is 43.02.
Transactions by insiders
Recent insider trading involved Khattar Jack A., President, CEO, that happened on Oct 09 ’25 when 59900.0 shares were sold. Director, NEWHALL CHARLES W III completed a deal on Oct 09 ’25 to sell 25000.0 shares. Meanwhile, Director JACK A. KHATTAR bought 59900.0 shares on Oct 09 ’25.
